Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

(2012) Grit Hutter et al.   ANNALS OF HEMATOLOGY

The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies

(2012) Kiyotaka Kawauchi et al.   Anti-Cancer Agents in Medicinal Chemistry

A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential

(2012) Chung-Gi Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen

(2012) Haitao Bai et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance

(2012) MARGARET E. TOME et al.   Experimental and Therapeutic Medicine

The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma

(2011) Ana Mozos et al.   AMERICAN JOURNAL OF PATHOLOGY

A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

(2011) J. E. Lancet et al.   CLINICAL CANCER RESEARCH

Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma

(2011) T. S. Lewis et al.   CLINICAL CANCER RESEARCH

Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines

(2011) Malin Ageberg et al.   EXPERIMENTAL CELL RESEARCH

The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation

(2011) E Rao et al.   LEUKEMIA

Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma

(2011) Hyun Joo Jung et al.   LEUKEMIA & LYMPHOMA

Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma

(2011) Steve A. Maxwell et al.   LEUKEMIA & LYMPHOMA

ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma

(2011) R R Singh et al.   ONCOGENE

The complex landscape of genetic alterations in mantle cell lymphoma

(2011) Cristina Royo et al.   SEMINARS IN CANCER BIOLOGY

Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies

(2011) Jonathan H. Schatz   Current Oncology Reports

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim

(2010) L. Happo et al.   BLOOD

Mantle cell lymphoma activation enhances bortezomib sensitivity

(2010) S. K. Brennan et al.   BLOOD

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2010) Sverker Hasselblom et al.   BRITISH JOURNAL OF HAEMATOLOGY

DNA Damage-Mediated Induction of a Chemoresistant Niche

(2010) Luke A. Gilbert et al.   CELL

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma

(2010) Shahab Uddin et al.   LABORATORY INVESTIGATION

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma

(2010) Shahab Uddin et al.   LEUKEMIA & LYMPHOMA

Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells

(2009) Li Jia et al.   ANNALS OF HEMATOLOGY

Circulating clonotypic B cells in classic Hodgkin lymphoma

(2009) R. J. Jones et al.   BLOOD

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

(2009) M. Gupta et al.   BLOOD

How I treat mantle cell lymphoma

(2009) M. Ghielmini et al.   BLOOD

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

(2009) N. Eckstein et al.   CANCER RESEARCH

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

(2009) S. Bhalla et al.   CLINICAL CANCER RESEARCH

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

(2009) Mark Prichard et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma

(2009) Xianfeng Frank Zhao et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

14-3-3ζ Mediates Resistance of Diffuse Large B Cell Lymphoma to an Anthracycline-based Chemotherapeutic Regimen

(2009) Steve A. Maxwell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma

(2009) C. Annette Hollmann et al.   LEUKEMIA RESEARCH

Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma

(2009) Ji Eun Kim et al.   MODERN PATHOLOGY

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling

(2008) R. J. Byers et al.   BLOOD

Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

(2008) Barbara Pro et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma

(2008) Johan Linderoth et al.   BRITISH JOURNAL OF HAEMATOLOGY

BCL6 Represses Smad Signaling in Transforming Growth Factor-  Resistance

(2008) D. Wang et al.   CANCER RESEARCH

Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

(2008) Y. Dai et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

(2008) S. H. Olejniczak et al.   CLINICAL CANCER RESEARCH

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

(2008) M. B. Meads et al.   CLINICAL CANCER RESEARCH

Mantle cell lymphoma: advances in biology and therapy

(2008) Mitchell R Smith   CURRENT OPINION IN HEMATOLOGY

Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma

(2008) Yu Baohua et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

Diffuse Large B-Cell Lymphoma

(2008) Jonathan W. Friedberg et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Therapy of Mantle Cell Lymphoma: Current Standards and Future Strategies

(2008) Christian Schmidt et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling

(2008) Claire A. Walshe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Akt Regulates the Survival of Vascular Smooth Muscle Cells via Inhibition of FoxO3a and GSK3

(2008) David Allard et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chemical Biology Investigation of Cell Death Pathways Activated by Endoplasmic Reticulum Stress Reveals Cytoprotective Modulators of ASK1

(2008) InKi Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PP2A Regulates the Pro-apoptotic Activity of FOXO1

(2008) Ling Yan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis

(2008) L Gu et al.   LEUKEMIA

Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis

(2008) T Lwin et al.   LEUKEMIA

Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers ofin vivoresponse

(2008) Jane Houldsworth et al.   LEUKEMIA & LYMPHOMA

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

(2008) Edgar Gil Rizzatti et al.   LEUKEMIA & LYMPHOMA

Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions

(2008) Michael G. Bayerl et al.   LEUKEMIA & LYMPHOMA

Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy

(2008) Kaname Miyashita et al.   LEUKEMIA RESEARCH

PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines

(2008) Mariana G. García et al.   LEUKEMIA RESEARCH

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- B, p53, bax, and p27 levels

(2008) C. A. Tucker et al.   MOLECULAR CANCER THERAPEUTICS

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

(2008) Xiang-Jiao Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

Novel therapies in peripheral T-cell lymphomas

(2008) Hilary M. O’Leary et al.   Current Hematologic Malignancy Reports

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

(2007) E. Vellenga et al.   BLOOD

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

(2007) Rongshi Li et al.   MEDICINAL RESEARCH REVIEWS